Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo
about
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer modelPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsTaxanes for adjuvant treatment of early breast cancerImproving symptom communication through personal digital assistants: the CHAT (Communicating Health Assisted by Technology) project.Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.Presentation and management of docetaxel-related adverse effects in patients with breast cancerThe use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Chemotherapy in early breast cancer: when, how and which one?Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Heath-related quality of life in Spanish breast cancer patients: a systematic review.Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.Refining docetaxel-containing therapy for gastric cancer.Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialThe impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyComparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines.Quality of life and adjuvant systemic therapy for early-stage breast cancer.Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extractHealth-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyPrognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.Capecitabine and docetaxel combination for the treatment of breast cancer.Delayed emotional recovery after taxane-based chemotherapy.Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.A systematic review of utility values for chemotherapy-related adverse events.
P2860
Q21090788-17A90074-11AA-4ACB-9D53-417FE50BF13BQ24198118-72C41637-87FD-410D-8B4C-BF1818DBD22DQ24242987-96D12C6E-77DD-4075-A08B-30BB358689B5Q30562213-8227E01D-A9A4-4EDC-8A53-C0C12CE01329Q33441582-7A10523F-7867-4964-810F-9A3490926E75Q33539387-EEE4E010-42E0-4E3C-A8AD-245561D69364Q33680393-303B4EE2-58EC-4686-88B0-EF9839D29646Q33698286-B1DA74BD-C29C-4C67-BA10-1DCA9861E15EQ33752272-2B31AFC8-1C45-43BD-A2D6-0D6B7E17AC9DQ33756369-1BF1957A-E1E5-4D9C-A498-8CA05F093F93Q33785011-5504DB4D-CE76-4ECB-8653-A3E7763B3299Q34042640-741E6A2B-481C-453A-8988-F86B2CEEBFC1Q34071621-F7197C86-4BFD-46E5-8DC7-82ABCEDC1D12Q34095827-F6FF317E-AC88-44FB-9C6D-481A2AE302D6Q34199348-54883B7B-45C3-4F64-939F-402B8898D192Q34540772-DAAFD54A-5A16-470C-AE88-CDAA0C4EA655Q34818002-BDF3D697-1B3C-4DA1-97C2-5021655139C2Q35237134-82C6613E-73C2-473F-8E57-62C76ED3EA4AQ35445166-BA5B3B9D-AA1E-44C0-A6C5-95B6FADEC586Q35599471-FBDC0642-3BF0-4B71-B445-2812899C33BFQ35889568-FC1B22DF-DEC2-4CA9-86F9-64C2EB0FE35CQ35916166-9B578CBA-3198-4FFB-BDB8-580A376546E5Q35948108-D40840BE-5B22-40E9-9687-A38B4CD4CBA6Q36004954-E69F8944-3E12-4DBA-8C6E-95F0121ACFB5Q36449309-AF2836EA-32CF-4BFA-842B-29AE64801F9FQ36485208-AFCBD322-55A1-4631-B6F0-4332325FD2C6Q36615056-4CA8C313-8C5C-4931-A04E-2B67338EB316Q36870783-51FC1C15-7607-4043-A60E-A7FF8C809A4BQ37008863-899380F8-D9A9-48CD-BDDF-9F439B80B809Q37014753-0AED75DD-6127-42FD-BA0C-F8A1ACD8DD11Q37038467-C89EF587-BABA-405B-9494-5B1BC40131D8Q37205943-F1096EB1-C3AC-4E5C-983F-D4BEFFC7FD58Q37346070-09BAA04F-690B-418F-84B8-9649AFA9DFEEQ37352503-37AA36E8-4597-466C-B969-78791A36C2B0Q37398926-6B2D1163-2BFD-4DA3-B9A1-556AE74733F6Q37684270-9D0B82FE-2BA8-4743-816C-31D3370F403FQ37694174-757FAFF5-9F0A-4CCE-A722-194DD9DE4CFBQ37827010-BDE572A1-CC9B-46FD-87A0-638BAB7B1BF3Q37976586-0CC7F6D0-6A99-4A68-95BE-961C6681BBB1Q38093053-05CB0D57-7B8A-4183-A2DB-D60D794DA068
P2860
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Toxicity and health-related qu ...... prophylactic granulocyte-colo
@en
type
label
Toxicity and health-related qu ...... prophylactic granulocyte-colo
@en
prefLabel
Toxicity and health-related qu ...... prophylactic granulocyte-colo
@en
P2093
P356
P1433
P1476
Toxicity and health-related qu ...... prophylactic granulocyte-colo
@en
P2093
A Rodríguez-Lescure
C Fernandez-Chacón
J M López-Vega
P304
P356
10.1093/ANNONC/MDL135
P577
2006-06-09T00:00:00Z